跳至主要内容
临床试验/NCT06964724
NCT06964724进行中(未招募)不适用

NeVa International, MulTi-center, Retrospective cOmparative Stent Retriever Study

Vesalio5 个研究点 分布在 5 个国家目标入组 800 人开始时间: 2025年6月15日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
800
试验地点
5
主要终点
Reperfusion Effectiveness

研究概览

简要总结

To compare safety and effectiveness of NeVa Stent Retriever (SR) to Control SR in the treatment of stroke caused by large vessel occlusion. The main questions it aims to answer are:

How do recanalization rates for NeVa SR compare with those of the Control SR? How does NeVa SR safety compare with Control SR safety?

详细描述

NITRO is a multicenter, retrospective, comparative, non-inferiority, cohort study designed to compare NeVa SR with Control SR for safety and effectiveness when removing thrombus in subjects presenting with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The objective of the NeVa International, Multi-center, Retrospective Comparative stent retriever (SR) study (NITRO) study is to compare safety and effectiveness of the NeVa SR to commonly used SR with CE-mark, and US FDA clearance, to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion. NITRO aims to collect data describing real-world clinical practices when using SRs according to their indicated use within the indicated population. As such, the eligibility criteria define patients who are diagnosed with AIS and are indicated for endovascular MT aligning to the target population for the proposed device. The present study will include data from subjects treated with either NeVa SR or one of the Control SR. Control SR will include any SR commonly used in thrombectomy trials as first-line strategies and which represent CE-mark, and US FDA cleared stent retrievers.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Treatment during the enrollment period
  • Baseline modified Thrombolysis in Cerebral Infarction (mTICI) score ≤ 1
  • Pre-stroke modified Rankin score (mRS) of 0 or 1
  • Internal Carotid Artery (ICA), Middle Cerebral Artery (first segment M1/ second segment M2), basilar artery or vertebral artery occlusion
  • National Institutes of Health Stroke Scale (NIHSS) score ≥ 8 and ≤ 25
  • Thrombectomy procedure initiated within 8h of Time Last Known Well (TLKW)
  • Intravenous Tissue Plasminogen Activator (IV-tPA) failed, given within 3h of TLKW, or ineligibility for thrombolytic drug

排除标准

  • First line contact aspiration alone or non-study device as first-line device

结局指标

主要结局

Reperfusion Effectiveness

时间窗: Procedural

Number of patients with a Modified Thrombolysis in cerebral infarction (mTICI) ≥2B and mTICI≥2C recanalization after 1st pass and at end of procedure

次要结局

  • Procedure Safety(Within 24 hours post intervention)
  • Device relationship to serious adverse events(Within 24 hours post intervention)
  • Procedural symptomatic bleeding events(Within 24 hours post intervention)

研究者

发起方
Vesalio
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验